Skip to main content
Eurosurveillance logoLink to Eurosurveillance
letter
. 2019 Jun 20;24(25):1900355. doi: 10.2807/1560-7917.ES.2019.24.25.1900355

Letter to the editor: Strengthening epidemiological surveillance of Neisseria gonorrhoea – beyond the detection of cases

Victoria Hernando 1, Alicia Magistris 2, Antonio Nicolau 3, Susana Ramón 4, Carmen Varela 1, Marta Ruiz-Algueró 1, Asunción Diaz 1
PMCID: PMC6593903  PMID: 31241038

To the editor: We have read the interesting article by Eyre DW et al. describing a Neisseria gonorrhoea (NG) FC428 clone detected in two female cases who developed infection following contact with United Kingdom (UK)-resident men linked to travel to Ibiza, Spain. These cases provide evidence that the FC428 clone’s transmission is occurring within Europe. The widespread distribution of this clone threatens the effectiveness of gonorrhoea treatment [1].

As both cases had contact with the same sexual network in Ibiza, an exhaustive search of other probable NG cases was developed by the national and local public health authorities. During 2018, 82 cases of gonorrhoea were diagnosed in Ibiza; 80% (n = 66) were men with a median age of 29 years (interquartile range (IQR): 25–36) and 20% (n = 16) were women with a median age of 32.5 years (IQR: 27.5–37.5). Forty percent of the cases (n = 33) were foreigners, but none of them were tourists. Among the foreigners, 26 were men, 20 were from Europe (half of which were from Italy) and 12 were from Latin America. The most common clinical presentation was urethritis among men (62/66) and cervicitis among women (15/16).

A positive culture was confirmed in 90% (n = 74) of the cases; 91% (n=60/66) of cultures were positive among men and 87% (14/16) among women. Of the 82 NG isolates tested, 26.8% showed resistance to penicillin (intermediate susceptibility), 2.4% to ciprofloxacin and 11% to both antibiotics. Resistance to ciprofloxacin and levofloxacin was found in 11% (n = 9) of isolated strains, and 15.8% (n = 13) showed additional resistance to penicillin. Two strains showed resistance to ciprofloxacin, levofloxacin and cefuroxime. None of the isolated and tested strains showed resistance to ceftriaxone. In Ibiza there are two hospitals, one public and one private. The notification of gonococcal cases are compulsory in both hospitals. No positive cases were diagnosed in the private hospital in 2018, and all previously described cases were diagnosed in the public hospital.

The incidence rate of gonococcal infection has increased in Spain since 2001. From 2001–13, the annual change was 11.7% (95% confidence interval (CI): 9.6–13.9) and from 2013–17 it was 26.3% (95% CI: 20.7–32.2). In 2017, the Balearic Islands had one of the highest incidence rates in Spain, with 41.79 cases per 100,000 population [2].

In 2011, the first two cases of ceftriaxone-resistant NG were reported in Catalonia, Spain. Both cases were men who have sex with men (MSM). One of the cases was diagnosed with urethral discharge by a general practitioner. He was treated with 100 mg of doxycycline twice a day for 7 days. The other case was his partner and was asymptomatic, with no signs of proctitis or urethritis. He was treated with levofloxacin for 7 days. In both cases, ceftriaxone-resistant NG strains were isolated [3]; these were the third and fourth ceftriaxone-resistant NG strains isolated in Europe and were genetically related to the strain isolated in France [4]. As all cases were MSM, there is strong indication that resistance clones may circulate in this community.

Spain is one of the participating countries in the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) [5]. In its last report, published in 2018, cefixime resistance was isolated from 1.6% of the 365 tested isolates submitted from Spain, but no ceftriaxone resistance was identified. Nevertheless, it is necessary to anticipate an emergency situation in which treatment of NG infection can fail. International travel and new technologies such as social media and dating apps can contribute to the spread of new resistance strains that can compromise NG treatment effectiveness. It is therefore important that we reinforce communication among the countries that are facing this global challenge. At the national level, a multidisciplinary approach is needed, so clinicians, microbiologists, epidemiologists and public health authorities should be involved. Spain has developed a national plan against antimicrobial resistance that includes gonococcal infection as a global threat. One of the milestones of this plan is to reinforce the surveillance and control of antimicrobial resistance.

Acknowledgements

We would like to acknowledge Maribel Medina, Microbiology Laboratory of Policlínica Nuestra Señora del Rosario, Ibiza.

Conflict of interest: None declared.

Authors’ contributions: VH wrote the first draft of the manuscript. VH, MR, CV and AD formed part of the outbreak research team of sexually transmitted infections. AM, AN and SR formed part of outbreak research team in the Balearic Islands. All authors reviewed the final version of the manuscript.

References

  • 1. Eyre DW, Town K, Street T, Barker L, Sanderson N, Cole MJ, et al. Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Euro Surveill. 2019;24(10):1900147. 10.2807/1560-7917.ES.2019.24.10.1900147 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Unidad de Vigilancia del VIH y conductas de riesgo [HIV Surveillance and Behavioral Monitoring Unit]. Vigilancia epidemiológica de las infecciones de transmisión sexual, 2017. [Epidemiological surveillance of Sexually Transmitted Infections in Spain, 2017]. Madrid: Centro Nacional de Epidemiología - Instituto de Salud Carlos III/Plan Nacional sobre el Sida-S.G. de Promoción de la Salud y Vigilancia en Salud Pública; 2019.Spanish. Available from: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-sida/vigilancia-de-conductas-de-riesgo-para-el-VIH.shtml
  • 3. Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67(8):1858-60. 10.1093/jac/dks162 [DOI] [PubMed] [Google Scholar]
  • 4. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273-80. 10.1128/AAC.05760-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.European Centre for Disease Prevention and Control (ECDC). Gonococcal antimicrobial susceptibility surveillance in Europe. Stockholm: ECDC; 2018. Available from: https://ecdc.europa.eu/sites/portal/files/documents/EURO-GASP-report-2016.pdf

Articles from Eurosurveillance are provided here courtesy of European Centre for Disease Prevention and Control

RESOURCES